Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5 a.m.

    📋 Arbutus Biopharma Corporation (ABUS) - Clinical Trial Update

    Filing Date: 2022-06-08

    Accepted: 2022-06-08 06:00:24

    Event Type: Clinical Trial Update

    Event Details:

    Arbutus Biopharma Corporation (ABUS) Announces Clinical Trial Update Arbutus Biopharma Corporation (ABUS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: scheduled
    • Diseases/Conditions: June 27
    • Collaboration: EASL International Liver Congress

    🔬 Clinical Development Pipeline (Arbutus Biopharma Corporation):

    Product Type Development Stage Therapeutic Area Source
    Imdusiran (AB-729) DRUG Phase PHASE2 Chronic Hepatitis B ClinicalTrials.gov
    AB-101 DRUG Phase PHASE1 Chronic Hepatitis b ClinicalTrials.gov
    AB-729 DRUG Phase PHASE2 Chronic Hepatitis b ClinicalTrials.gov
    AB-836 DRUG Phase PHASE1 Chronic Hepatitis ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Hypercholesterolemia ClinicalTrials.gov
    PRO-040201 DRUG Phase PHASE1 Hypercholesterolemia ClinicalTrials.gov
    TKM-100802 for Injection DRUG Phase PHASE1 Ebola Virus Infection ClinicalTrials.gov
    TKM-100201 DRUG Phase PHASE1 Ebola Virus Infection ClinicalTrials.gov
    ARB-001467 DRUG Phase PHASE2 Hepatitis B, Chronic ClinicalTrials.gov
    L-DOS47 DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    TKM-080301 DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Nucleos(t)ide Analogue DRUG Phase PHASE1 Chronic Hepatitis ClinicalTrials.gov
    Durvalumab DRUG Phase PHASE2 Hepatitis B, Chronic ClinicalTrials.gov
    Imdusiran DRUG Phase PHASE2 Hepatitis B, Chronic ClinicalTrials.gov
    Non-interventional OTHER Preclinical Long Term Follow-up ClinicalTrials.gov
    Peg-IFNα-2a DRUG Phase PHASE2 Chronic Hepatitis b ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Arbutus Biopharma Corporation
    • CIK: 0001447028
    • Ticker Symbol: ABUS
    • Period End Date: 2022-06-08
    • Document Type: 8-K

Search

News categories